Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis

Yumin Xia, Sean R. Campbell, Anna R. Broder, Leal Herlitz, Maria Abadi, Ping Wu, Jennifer S. Michaelson, Linda C. Burkly, Chaim Putterman

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Previously it was shown that the TNF superfamily member TWEAK (TNFSF12) acts through its receptor, Fn14, to promote proinflammatory responses in kidney cells, including the production of MCP-1, RANTES, IP-10 and KC. In addition, the TWEAK/Fn14 pathway promotes mesangial cell proliferation, vascular cell activation, and renal cell death. To study the relevance of the TWEAK/Fn14 pathway in the pathogenesis of antibody-induced nephritis using the mouse model of nephrotoxic serum nephritis (NTN), we induced NTN by passive transfer of rabbit anti-glomerular antibodies into Fn14 knockout (KO) and wild type (WT) mice. Severe proteinuria as well as renal histopathology were induced in WT but not in Fn14 KO mice. Similarly, a pharmacologic approach of anti-TWEAK mAb administration into WT mice in the NTN model significantly ameliorated proteinuria and improved kidney histology. Anti-TWEAK treatment did not affect the generation of mouse anti-rabbit antibodies; however, within the kidney there was a significant decrease in glomerular immunoglobulin deposition, as well as macrophage infiltrates and tubulointerstitial fibrosis. The mechanism of action is most likely due to reductions in downstream targets of TWEAK/Fn14 signaling, including reduced renal expression of MCP-1, VCAM-1, IP-10, RANTES as well as Fn14 itself, and other molecular pathways associated with fibrosis in anti-TWEAK treated mice. Thus, TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the NTN model, apparently mediating a cascade of pathologic events locally in the kidney rather than by impacting the systemic immune response. Disrupting TWEAK/Fn14 interactions may be an innovative kidney-protective approach for the treatment of lupus nephritis and other antibody-induced renal diseases.

Original languageEnglish (US)
Pages (from-to)108-121
Number of pages14
JournalClinical Immunology
Volume145
Issue number2
DOIs
StatePublished - Nov 2012

Fingerprint

Nephritis
Kidney
Serum
Chemokine CCL5
Proteinuria
Knockout Mice
Anti-Idiotypic Antibodies
Fibrosis
Rabbits
Lupus Nephritis
Mesangial Cells
Vascular Cell Adhesion Molecule-1
Antibodies
Blood Vessels
Immunoglobulins
Histology
Cell Death
Macrophages
Cell Proliferation
Therapeutics

Keywords

  • Fn14
  • Nephrotoxic serum nephritis
  • Systemic lupus erythematosus (SLE)
  • TWEAK

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. / Xia, Yumin; Campbell, Sean R.; Broder, Anna R.; Herlitz, Leal; Abadi, Maria; Wu, Ping; Michaelson, Jennifer S.; Burkly, Linda C.; Putterman, Chaim.

In: Clinical Immunology, Vol. 145, No. 2, 11.2012, p. 108-121.

Research output: Contribution to journalArticle

Xia, Y, Campbell, SR, Broder, AR, Herlitz, L, Abadi, M, Wu, P, Michaelson, JS, Burkly, LC & Putterman, C 2012, 'Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis', Clinical Immunology, vol. 145, no. 2, pp. 108-121. https://doi.org/10.1016/j.clim.2012.08.008
Xia, Yumin ; Campbell, Sean R. ; Broder, Anna R. ; Herlitz, Leal ; Abadi, Maria ; Wu, Ping ; Michaelson, Jennifer S. ; Burkly, Linda C. ; Putterman, Chaim. / Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. In: Clinical Immunology. 2012 ; Vol. 145, No. 2. pp. 108-121.
@article{87446d1939e64fa48ec61baca6fe02a3,
title = "Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis",
abstract = "Previously it was shown that the TNF superfamily member TWEAK (TNFSF12) acts through its receptor, Fn14, to promote proinflammatory responses in kidney cells, including the production of MCP-1, RANTES, IP-10 and KC. In addition, the TWEAK/Fn14 pathway promotes mesangial cell proliferation, vascular cell activation, and renal cell death. To study the relevance of the TWEAK/Fn14 pathway in the pathogenesis of antibody-induced nephritis using the mouse model of nephrotoxic serum nephritis (NTN), we induced NTN by passive transfer of rabbit anti-glomerular antibodies into Fn14 knockout (KO) and wild type (WT) mice. Severe proteinuria as well as renal histopathology were induced in WT but not in Fn14 KO mice. Similarly, a pharmacologic approach of anti-TWEAK mAb administration into WT mice in the NTN model significantly ameliorated proteinuria and improved kidney histology. Anti-TWEAK treatment did not affect the generation of mouse anti-rabbit antibodies; however, within the kidney there was a significant decrease in glomerular immunoglobulin deposition, as well as macrophage infiltrates and tubulointerstitial fibrosis. The mechanism of action is most likely due to reductions in downstream targets of TWEAK/Fn14 signaling, including reduced renal expression of MCP-1, VCAM-1, IP-10, RANTES as well as Fn14 itself, and other molecular pathways associated with fibrosis in anti-TWEAK treated mice. Thus, TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the NTN model, apparently mediating a cascade of pathologic events locally in the kidney rather than by impacting the systemic immune response. Disrupting TWEAK/Fn14 interactions may be an innovative kidney-protective approach for the treatment of lupus nephritis and other antibody-induced renal diseases.",
keywords = "Fn14, Nephrotoxic serum nephritis, Systemic lupus erythematosus (SLE), TWEAK",
author = "Yumin Xia and Campbell, {Sean R.} and Broder, {Anna R.} and Leal Herlitz and Maria Abadi and Ping Wu and Michaelson, {Jennifer S.} and Burkly, {Linda C.} and Chaim Putterman",
year = "2012",
month = "11",
doi = "10.1016/j.clim.2012.08.008",
language = "English (US)",
volume = "145",
pages = "108--121",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis

AU - Xia, Yumin

AU - Campbell, Sean R.

AU - Broder, Anna R.

AU - Herlitz, Leal

AU - Abadi, Maria

AU - Wu, Ping

AU - Michaelson, Jennifer S.

AU - Burkly, Linda C.

AU - Putterman, Chaim

PY - 2012/11

Y1 - 2012/11

N2 - Previously it was shown that the TNF superfamily member TWEAK (TNFSF12) acts through its receptor, Fn14, to promote proinflammatory responses in kidney cells, including the production of MCP-1, RANTES, IP-10 and KC. In addition, the TWEAK/Fn14 pathway promotes mesangial cell proliferation, vascular cell activation, and renal cell death. To study the relevance of the TWEAK/Fn14 pathway in the pathogenesis of antibody-induced nephritis using the mouse model of nephrotoxic serum nephritis (NTN), we induced NTN by passive transfer of rabbit anti-glomerular antibodies into Fn14 knockout (KO) and wild type (WT) mice. Severe proteinuria as well as renal histopathology were induced in WT but not in Fn14 KO mice. Similarly, a pharmacologic approach of anti-TWEAK mAb administration into WT mice in the NTN model significantly ameliorated proteinuria and improved kidney histology. Anti-TWEAK treatment did not affect the generation of mouse anti-rabbit antibodies; however, within the kidney there was a significant decrease in glomerular immunoglobulin deposition, as well as macrophage infiltrates and tubulointerstitial fibrosis. The mechanism of action is most likely due to reductions in downstream targets of TWEAK/Fn14 signaling, including reduced renal expression of MCP-1, VCAM-1, IP-10, RANTES as well as Fn14 itself, and other molecular pathways associated with fibrosis in anti-TWEAK treated mice. Thus, TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the NTN model, apparently mediating a cascade of pathologic events locally in the kidney rather than by impacting the systemic immune response. Disrupting TWEAK/Fn14 interactions may be an innovative kidney-protective approach for the treatment of lupus nephritis and other antibody-induced renal diseases.

AB - Previously it was shown that the TNF superfamily member TWEAK (TNFSF12) acts through its receptor, Fn14, to promote proinflammatory responses in kidney cells, including the production of MCP-1, RANTES, IP-10 and KC. In addition, the TWEAK/Fn14 pathway promotes mesangial cell proliferation, vascular cell activation, and renal cell death. To study the relevance of the TWEAK/Fn14 pathway in the pathogenesis of antibody-induced nephritis using the mouse model of nephrotoxic serum nephritis (NTN), we induced NTN by passive transfer of rabbit anti-glomerular antibodies into Fn14 knockout (KO) and wild type (WT) mice. Severe proteinuria as well as renal histopathology were induced in WT but not in Fn14 KO mice. Similarly, a pharmacologic approach of anti-TWEAK mAb administration into WT mice in the NTN model significantly ameliorated proteinuria and improved kidney histology. Anti-TWEAK treatment did not affect the generation of mouse anti-rabbit antibodies; however, within the kidney there was a significant decrease in glomerular immunoglobulin deposition, as well as macrophage infiltrates and tubulointerstitial fibrosis. The mechanism of action is most likely due to reductions in downstream targets of TWEAK/Fn14 signaling, including reduced renal expression of MCP-1, VCAM-1, IP-10, RANTES as well as Fn14 itself, and other molecular pathways associated with fibrosis in anti-TWEAK treated mice. Thus, TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the NTN model, apparently mediating a cascade of pathologic events locally in the kidney rather than by impacting the systemic immune response. Disrupting TWEAK/Fn14 interactions may be an innovative kidney-protective approach for the treatment of lupus nephritis and other antibody-induced renal diseases.

KW - Fn14

KW - Nephrotoxic serum nephritis

KW - Systemic lupus erythematosus (SLE)

KW - TWEAK

UR - http://www.scopus.com/inward/record.url?scp=84866085652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866085652&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2012.08.008

DO - 10.1016/j.clim.2012.08.008

M3 - Article

C2 - 22982296

AN - SCOPUS:84866085652

VL - 145

SP - 108

EP - 121

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -